Back

A Novel Hydrogen Polysulfide Donor Alleviates Neuropathic Pain by Enhancing A-Type Potassium Currents via LIMK1-Cofilin Mediated Interaction between Filamin A and Kv4.2

Kang, T.; Jiao, Y.; Lai, S.; Tao, S.; Chen, C.; Cao, Z.; Yan, F.; Ding, Y.; Li, X.; Ke, B.

2026-05-28 pharmacology and toxicology
10.64898/2026.05.25.727751 bioRxiv
Show abstract

Hydrogen persulfide (H2S2) is an important endogenous signaling molecule, holding significant therapeutic potential across diverse disease models due to its potent antioxidant and redox-regulating properties. Herein, we report the synthesis, characterization, and in vivo evaluation of an esterase responsive H2S2 donor, HPD1. It reduced mechanical and cold allodynia at 14 mg/kg (i.p.) in chronic constriction injury and paclitaxel-induced neuropathic pain models. Moreover, HPD1 exhibited negligible systemic toxicity and behavioral side effects even at 28 mg/kg. Electrophysiological tests showed that HPD1 suppressed PTX-induced hyperexcitability in dorsal root ganglion (DRG) neurons by specifically potentiating A-type potassium currents (IA). Mechanistically, we demonstrate that HPD1 activates LIMK1, which inactivates cofilin and stabilizes F-actin, thereby promoting the interaction between the actin-binding protein Filamin A and Kv4.2. Furthermore, both the HPD1-induced increase in Filamin A-Kv4.2 co-localization and the subsequent restoration of IA density in DRG neurons, as well as the analgesic effect of HPD1 were dampened by pharmacological inhibition of LIMK1 with BMS-5. This work has developed a new generation of H2S2 donors, demonstrated the analgesic efficacy of HPD1, and uncovered the novel LIMK1-cofilin-Filamin A-Kv4.2 dependent mechanism that restores IA, thus providing a reliable therapeutic strategy for neuropathic pain based on H2S2 donors.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Advanced Science
249 papers in training set
Top 0.3%
18.5%
2
Journal of the American Chemical Society
199 papers in training set
Top 0.5%
12.2%
3
Angewandte Chemie International Edition
81 papers in training set
Top 0.3%
8.3%
4
Nature Communications
4913 papers in training set
Top 30%
6.3%
5
ACS Central Science
66 papers in training set
Top 0.3%
3.9%
6
ACS Medicinal Chemistry Letters
16 papers in training set
Top 0.2%
3.2%
50% of probability mass above
7
Signal Transduction and Targeted Therapy
29 papers in training set
Top 0.4%
3.0%
8
Journal of Medicinal Chemistry
68 papers in training set
Top 0.5%
2.3%
9
Redox Biology
64 papers in training set
Top 0.3%
2.1%
10
Chemical Science
71 papers in training set
Top 0.7%
2.1%
11
Acta Pharmaceutica Sinica B
11 papers in training set
Top 0.3%
2.1%
12
ACS Chemical Biology
150 papers in training set
Top 1%
1.7%
13
Bioorganic & Medicinal Chemistry Letters
10 papers in training set
Top 0.1%
1.7%
14
Advanced Healthcare Materials
71 papers in training set
Top 1%
1.7%
15
Nature Chemistry
34 papers in training set
Top 0.5%
1.5%
16
ChemMedChem
15 papers in training set
Top 0.4%
1.3%
17
Nucleic Acids Research
1128 papers in training set
Top 13%
1.3%
18
eLife
5422 papers in training set
Top 49%
1.2%
19
ACS Chemical Neuroscience
60 papers in training set
Top 2%
1.2%
20
Science Advances
1098 papers in training set
Top 24%
1.2%
21
Biomedicine & Pharmacotherapy
43 papers in training set
Top 0.6%
1.2%
22
Nature Chemical Biology
104 papers in training set
Top 3%
0.9%
23
Experimental & Molecular Medicine
14 papers in training set
Top 0.2%
0.8%
24
Chemistry – A European Journal
13 papers in training set
Top 0.6%
0.7%
25
Clinical and Translational Medicine
30 papers in training set
Top 1%
0.7%
26
Journal of Controlled Release
39 papers in training set
Top 1%
0.7%
27
Small
70 papers in training set
Top 1%
0.7%
28
Neurotherapeutics
11 papers in training set
Top 0.7%
0.6%
29
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 48%
0.6%
30
ACS Omega
90 papers in training set
Top 5%
0.6%